CHIME BIOLOGICS

Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab

Retrieved on: 
월요일, 5월 17, 2021
Science, Biotechnology, Research, Pharmaceutical, Other Manufacturing, Health, Infectious diseases, Manufacturing, Life sciences, Biotechnology, Health sciences, ISO 45001, Occupational safety and health, Biopharmaceutical, Chime Biologics, Humanigen, Inc., CHIME BIOLOGICS, HUMANIGEN, INC.

The cell culture capacity at the facility is 24,000L with planned expansion to 140,000L and Chime would be willing to commit at least 56,000L for Humanigen manufacture annually.

Key Points: 
  • The cell culture capacity at the facility is 24,000L with planned expansion to 140,000L and Chime would be willing to commit at least 56,000L for Humanigen manufacture annually.
  • Technical transfer work has already begun, and commercial product is planned to be available in 2022.\n\xe2\x80\x9cWe are pleased to have been selected by Humanigen as a manufacturing partner for ex-US supply of lenzilumab.
  • Since 2013, Chime Biologics has developed and produced more than 30 products and supplied to over 20 countries from its latest generation single use facility.
  • Chime Biologics is ISO 14001:2015 and ISO 45001:2018 certified, and is committed to uphold the highest degree of integrity.